Trends in antineoplastic receipt after medicare payment reform: Implications for future oncology payment design

Helen M Parsons, Susanne Schmidt, Laura L. Tenner, Amy J. Davidoff

Research output: Contribution to journalArticle

Abstract

Background: The Medicare Modernization Act (MMA) reduced reimbursement for many antineoplastics delivered in outpatient settings, altering practice patterns for some cancers. To further evaluate the MMA's effect, we focus on colon cancer, where longstanding fluorouracil-based regimens were augmented in 2004 with 3 newly-approved drugs (oxaliplatin, bevacizumab, and/or cetuximab). Staggered implementation of MMA reimbursement changes (physician offices implemented reimbursement changes in 2005 vs hospital outpatient departments(OPD) in 2006) provide a natural experiment to examine policy effects. Methods: Using the 2000–2009 SEER-Medicare data, we examined antineoplastic use among 59,642 stage II–IV colon cancer patients. Using multivariate logistic regression models, we conducted difference-in-differences analyses to examine an interaction between time (pre-post MMA) and setting (physician offices versus OPDs) on antineoplastic receipt, adjusting for patient and cancer characteristics. A significant interaction indicates different practice patterns in physician offices versus OPD during the staggered implementation. Results: After the reimbursement change in 2007–09 relative to 2000-03, use of fluorouracil-based therapy decreased slightly (Marginal Probability(MP): −0.07 stage II;−0.05 stage III;−0.05 stage IV; p < 0.01), while use of new drugs increased substantially (MP: 0.48 stage II; 0.69 stage III, 0.79 stage IV; p < 0.01). The interaction between MMA implementation and physician office setting was significant when examining use of new agents for Stage IV disease only. Conclusions: Our results indicate that providers responded to reimbursement changes after the MMA by increasing use of newly approved agents, but the magnitude of the response was small and limited to individuals diagnosed with Stage IV disease.

Original languageEnglish (US)
Pages (from-to)51-58
Number of pages8
JournalJournal of Cancer Policy
Volume17
DOIs
StatePublished - Sep 1 2018
Externally publishedYes

Fingerprint

Medicare
Antineoplastic Agents
Physicians' Offices
Social Change
oxaliplatin
Outpatients
Fluorouracil
Colonic Neoplasms
Logistic Models
Hospital Departments
Pharmaceutical Preparations
Neoplasms

Keywords

  • Colon cancer
  • Medicare Modernization Act
  • Policy
  • SEER-Medicare
  • Treatment

PubMed: MeSH publication types

  • Journal Article

Cite this

Trends in antineoplastic receipt after medicare payment reform : Implications for future oncology payment design. / Parsons, Helen M; Schmidt, Susanne; Tenner, Laura L.; Davidoff, Amy J.

In: Journal of Cancer Policy, Vol. 17, 01.09.2018, p. 51-58.

Research output: Contribution to journalArticle

@article{ea45e715f58542df8228bb1eb02d21ca,
title = "Trends in antineoplastic receipt after medicare payment reform: Implications for future oncology payment design",
abstract = "Background: The Medicare Modernization Act (MMA) reduced reimbursement for many antineoplastics delivered in outpatient settings, altering practice patterns for some cancers. To further evaluate the MMA's effect, we focus on colon cancer, where longstanding fluorouracil-based regimens were augmented in 2004 with 3 newly-approved drugs (oxaliplatin, bevacizumab, and/or cetuximab). Staggered implementation of MMA reimbursement changes (physician offices implemented reimbursement changes in 2005 vs hospital outpatient departments(OPD) in 2006) provide a natural experiment to examine policy effects. Methods: Using the 2000–2009 SEER-Medicare data, we examined antineoplastic use among 59,642 stage II–IV colon cancer patients. Using multivariate logistic regression models, we conducted difference-in-differences analyses to examine an interaction between time (pre-post MMA) and setting (physician offices versus OPDs) on antineoplastic receipt, adjusting for patient and cancer characteristics. A significant interaction indicates different practice patterns in physician offices versus OPD during the staggered implementation. Results: After the reimbursement change in 2007–09 relative to 2000-03, use of fluorouracil-based therapy decreased slightly (Marginal Probability(MP): −0.07 stage II;−0.05 stage III;−0.05 stage IV; p < 0.01), while use of new drugs increased substantially (MP: 0.48 stage II; 0.69 stage III, 0.79 stage IV; p < 0.01). The interaction between MMA implementation and physician office setting was significant when examining use of new agents for Stage IV disease only. Conclusions: Our results indicate that providers responded to reimbursement changes after the MMA by increasing use of newly approved agents, but the magnitude of the response was small and limited to individuals diagnosed with Stage IV disease.",
keywords = "Colon cancer, Medicare Modernization Act, Policy, SEER-Medicare, Treatment",
author = "Parsons, {Helen M} and Susanne Schmidt and Tenner, {Laura L.} and Davidoff, {Amy J.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.jcpo.2016.09.008",
language = "English (US)",
volume = "17",
pages = "51--58",
journal = "Journal of Cancer Policy",
issn = "2213-5383",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Trends in antineoplastic receipt after medicare payment reform

T2 - Implications for future oncology payment design

AU - Parsons, Helen M

AU - Schmidt, Susanne

AU - Tenner, Laura L.

AU - Davidoff, Amy J.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background: The Medicare Modernization Act (MMA) reduced reimbursement for many antineoplastics delivered in outpatient settings, altering practice patterns for some cancers. To further evaluate the MMA's effect, we focus on colon cancer, where longstanding fluorouracil-based regimens were augmented in 2004 with 3 newly-approved drugs (oxaliplatin, bevacizumab, and/or cetuximab). Staggered implementation of MMA reimbursement changes (physician offices implemented reimbursement changes in 2005 vs hospital outpatient departments(OPD) in 2006) provide a natural experiment to examine policy effects. Methods: Using the 2000–2009 SEER-Medicare data, we examined antineoplastic use among 59,642 stage II–IV colon cancer patients. Using multivariate logistic regression models, we conducted difference-in-differences analyses to examine an interaction between time (pre-post MMA) and setting (physician offices versus OPDs) on antineoplastic receipt, adjusting for patient and cancer characteristics. A significant interaction indicates different practice patterns in physician offices versus OPD during the staggered implementation. Results: After the reimbursement change in 2007–09 relative to 2000-03, use of fluorouracil-based therapy decreased slightly (Marginal Probability(MP): −0.07 stage II;−0.05 stage III;−0.05 stage IV; p < 0.01), while use of new drugs increased substantially (MP: 0.48 stage II; 0.69 stage III, 0.79 stage IV; p < 0.01). The interaction between MMA implementation and physician office setting was significant when examining use of new agents for Stage IV disease only. Conclusions: Our results indicate that providers responded to reimbursement changes after the MMA by increasing use of newly approved agents, but the magnitude of the response was small and limited to individuals diagnosed with Stage IV disease.

AB - Background: The Medicare Modernization Act (MMA) reduced reimbursement for many antineoplastics delivered in outpatient settings, altering practice patterns for some cancers. To further evaluate the MMA's effect, we focus on colon cancer, where longstanding fluorouracil-based regimens were augmented in 2004 with 3 newly-approved drugs (oxaliplatin, bevacizumab, and/or cetuximab). Staggered implementation of MMA reimbursement changes (physician offices implemented reimbursement changes in 2005 vs hospital outpatient departments(OPD) in 2006) provide a natural experiment to examine policy effects. Methods: Using the 2000–2009 SEER-Medicare data, we examined antineoplastic use among 59,642 stage II–IV colon cancer patients. Using multivariate logistic regression models, we conducted difference-in-differences analyses to examine an interaction between time (pre-post MMA) and setting (physician offices versus OPDs) on antineoplastic receipt, adjusting for patient and cancer characteristics. A significant interaction indicates different practice patterns in physician offices versus OPD during the staggered implementation. Results: After the reimbursement change in 2007–09 relative to 2000-03, use of fluorouracil-based therapy decreased slightly (Marginal Probability(MP): −0.07 stage II;−0.05 stage III;−0.05 stage IV; p < 0.01), while use of new drugs increased substantially (MP: 0.48 stage II; 0.69 stage III, 0.79 stage IV; p < 0.01). The interaction between MMA implementation and physician office setting was significant when examining use of new agents for Stage IV disease only. Conclusions: Our results indicate that providers responded to reimbursement changes after the MMA by increasing use of newly approved agents, but the magnitude of the response was small and limited to individuals diagnosed with Stage IV disease.

KW - Colon cancer

KW - Medicare Modernization Act

KW - Policy

KW - SEER-Medicare

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85006288724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006288724&partnerID=8YFLogxK

U2 - 10.1016/j.jcpo.2016.09.008

DO - 10.1016/j.jcpo.2016.09.008

M3 - Article

VL - 17

SP - 51

EP - 58

JO - Journal of Cancer Policy

JF - Journal of Cancer Policy

SN - 2213-5383

ER -